AIDS Vaccine Research: An overview (2013)
Use of Injectable Contraceptives and HIV Acquisition: The data to-date
Planned PrEP Demonstration Projects in Resource-Poor Settings
Clinical Trial Evidence for Oral and Topical Tenofovir-Based Prevention
ARV-Based Prevention Research and Development Product Pipeline: A Research Timeline
This timeline shows efficacy trials, related confirmatory studies and dates of possible regulatory submission for a range of ARV-based prevention options.
The Tipping Point
One way to measure progress in fighting AIDS is to compare the number of new HIV infections with the increase in HIV positive people on antiretroviral therapy (ART) over a given time period. An AIDS epidemic reaches its “tipping point” when the number of annual new HIV infection falls below the annual increase in patients starting ART. Coverage matters. A first milestone is treating approximately two thirds of people in need in a given country. Once that level is reached, countries and advocates can track progress to the tipping point.
From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape
The Vaccines Microbicides Resource Tracking Working Group, comprised of AVAC, the International AIDS Vaccine Initiative (IAVI), and the Joint United Nations Programme on HIV/AIDS (UNAIDS), uses a comprehensive methodology to track annual research and development investment trends in biomedical HIV prevention.
Ending AIDS Gamechangers
From the Ending AIDS report, a joint partnership between AVAC and amfAR. Visit www.endingaids.org for more information.
Trial Participants as Research Investors
ARV-Based Prevention Research and Development Product Pipeline
The Px Wire centerspread from April-June 2013 Volume 6, No. 2 showcases the ARV-based HIV prevention pipeline from pre-clinical research to implementation projects.